- Home
- AVDL vs CVAC Comparison
AVDL vs CVAC Comparison
Compare AVDL & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVDL
- CVAC
- Stock Information
- Founded
- AVDL 2015
- CVAC 2000
- Country
- AVDL Ireland
- CVAC Germany
- Employees
- AVDL N/A
- CVAC N/A
- Industry
- AVDL Biotechnology: Pharmaceutical Preparations
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- AVDL Health Care
- CVAC Health Care
- Exchange
- AVDL Nasdaq
- CVAC Nasdaq
- Market Cap
- AVDL 784.6M
- CVAC 818.8M
- IPO Year
- AVDL 1996
- CVAC 2020
- Fundamental
- Price
- AVDL $8.03
- CVAC $3.12
- Analyst Decision
- AVDL Strong Buy
- CVAC Buy
- Analyst Count
- AVDL 7
- CVAC 2
- Target Price
- AVDL $18.86
- CVAC $10.00
- AVG Volume (30 Days)
- AVDL 1.1M
- CVAC 717.4K
- Earning Date
- AVDL 05-07-2025
- CVAC 04-10-2025
- Dividend Yield
- AVDL N/A
- CVAC N/A
- EPS Growth
- AVDL N/A
- CVAC N/A
- EPS
- AVDL N/A
- CVAC 0.75
- Revenue
- AVDL $169,117,000.00
- CVAC $554,073,921.00
- Revenue This Year
- AVDL $50.53
- CVAC N/A
- Revenue Next Year
- AVDL $32.33
- CVAC $66.34
- P/E Ratio
- AVDL N/A
- CVAC $4.19
- Revenue Growth
- AVDL 504.79
- CVAC 895.54
- 52 Week Low
- AVDL $6.38
- CVAC $2.22
- 52 Week High
- AVDL $19.09
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- AVDL 54.47
- CVAC 53.48
- Support Level
- AVDL $6.38
- CVAC $3.05
- Resistance Level
- AVDL $8.22
- CVAC $3.02
- Average True Range (ATR)
- AVDL 0.48
- CVAC 0.19
- MACD
- AVDL 0.11
- CVAC 0.06
- Stochastic Oscillator
- AVDL 89.67
- CVAC 79.14
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.